Conference Day One

For full session details, access the 2025 Full Event Guide here!

7:30 am Light Breakfast & Check-In

8:50 am Chair’s Opening Remarks

  • Yan Sun Senior Scientist, Entact Bio

Enhancing Mass Spectrometry Through Optimized DIA & TMT Workflows to Balance Speed & Sensitivity for Reliable Workflows

9:00 am Optimizing Data Independent Acquisition for Comprehensive Target Discovery & Occupancy Assays with Higher Reproducibility

Synopsis

  • Switching from a TMT focused approach to DIA for more reliable data acquisition
  • Ensuring comprehensive coverage of the screening pool for covalent drug discovery using DIA approaches
  • Enabling higher throughout DIA-based target occupancy assays to advance covalent drug development

9:30 am High-Throughput & Accurate Multiplexed Approach for Overcoming Bottlenecks in Large-Scale Proteomics

Synopsis

  • Deeply profiled over 300 tissue samples with TMT-based proteomics, completing sample preparation in under two weeks
  • Established high-throughput analysis with minimal sample-to-sample variability through an in-house developed robust, automated multiplexed proteomics platform
  • Achieved high quantification accuracy by utilizing ion data and a specific experimental design for precise protein quantification across numerous samples and acquisition runs

10:00 am Assays & Strategies to Interrogate the Proteome for Drug Discovery

  • Jan Schülke Head of Business Development, OmicScouts GmbH

Synopsis

  • How proteomics can create value in all stages of preclinical drug discovery
  • ProteomeScout™ HT is a fast and cost-effective assay for phenotypic characterization of compounds, to guide SAR and validate MOA
  • SideScout™ is a label-free assay for target engagement and selectivity profiling in lysates and live cells
  • Proteomic data products provide quick access to valuable information to drive decisions

10:15 am Morning Break & Speed Networking

Unveiling Protein-Protein Interactions: Advancing Protein Complex Studies Through Translational Proteomic for Informing Drug Development

11:15 am Decoding Protein Protein Interactions: Insights from Affinity Purification Mass Spectrometry and Convergent Network Analysis

Synopsis

  • Elucidation of novel drug targets using network analysis and APMS
  • The investigation of differential protein-protein interaction (PPI) networks in response to drugs
  • Leveraging complementary MS based proteomics approaches to gain further insight into PPIs and network biology

11:45 am Harnessing Disruptive Technology in a Service Laboratory: Proteomics in the Astral Era

Synopsis

  • Conversation about the impact of the Orbitrap Astral on routine and non-routine proteomics
  • Discussion on the recent past, near- and long-term future of mass spectrometry-based proteomics

12:15 pm Lunch Break & Networking

Optimizing Proteomics Approaches for Covalent Drug Discovery: Addressing Specificity, Probe Development, & Metabolite Challenges

1:15 pm Advancing Histidine, Tyrosine and Lysine (HYK) Covalent Probes in Mass Spectrometry

Synopsis

  • Using mass spectrometry to optimize probes for covalent targeting of HYK residues that can monitor novel pockets across the proteome
  • Developing methods for robust high-throughput mass spec analysis of HYK probelabeled peptides
  • Leveraging the HYKU platform to support covalent and non-covalent drug discovery programs

1:45 pm Harnessing Proteomics & Deep Learning Approaches to Enable Covalent Drug Discovery

Synopsis

  • Systematic and proteome-wide druggability of proteins in the native setting is synergistically enabled by the combination of Covalency and Mass Spectrometry
  • Deep Learning improves deconvolution of Mass Spectrometry-based Proteomics data and boosts the sequence coverage of Covalent Chemoproteomics
  • Structural Mass Spectrometry combined with machine learning for improved prediction of ligandability of residues, protein structure, and topology

2:15 pm Covalent Drug Discovery by Chemoproteomics: Deconvolution of Phenotypic Screening Hits Through IMTAC Proteome-Wide, Live-Cell Screening

  • Ning Deng Director, BridGene Biosciences Inc.

Synopsis

  • Discussing the advantages of IMTAC proteome-wide, live-cell screening to further drug discovery efforts
  • Identification of novel targets with the potential to overcome acquired chemotherapy resistance in high-grade serous ovarian cancer

2:45pm Afternoon Networking Break & Poster Session

Advancing Proteomic Approaches for the Discovery & Development of Improved Protein Degraders

3:45 pm Using Proteomics to Accelerate Drug Discovery in Targeted Protein Degradation

  • Alex Campos Senior Director - Systems Biology & Proteomics, Plexium Inc.

Synopsis

  • Application of mass spectrometry-based proteomics in TPD development process, from target identification and validation to protein-protein interaction
  • Proteomics strategies to dissect protein degradation mechanism
  • Optimizing LC-MS/MS methods to maximize throughput and sensitivity while balancing quality and data confidence
  • Streamlining data analysis to increase productivity and discovery of actionable drug targets

4:15 pm Leveraging Proteomics to Accelerate Target Identification for Molecular Glue Degraders

Synopsis

  • Developing proteomics platform for molecular glue degraders
  • Increasing Proteomics throughput using DIA approach to accelerate target identification
  • Combining proteomics, structural biology, and proximity labelling techniques to efficiently validate and characterize novel targets.

4:45 pm Chair’s Closing Remarks

  • Yan Sun Senior Scientist, Entact Bio

5:45 pm End of Conference Day One